AltPep
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 NE Northlake Way Ste 300, Seattle, W...Phone Number
(425) 658-0277Website
www.altpep.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About AltPep
AltPep Corporation is a biotechnology company focused on developing early disease-modifying treatments and detection tools for amyloid diseases, including Alzheimer's and Parkinson's. Their innovative platform utilizes custom-designed synthetic peptides to selectively target and neutralize toxic oligomers associated with these diseases. AltPep aims to enable early detection and intervention, potentially changing the course of amyloid diseases that affect over a billion people globally. The company is committed to transforming the diagnosis and treatment landscape for amyloid diseases through its pipeline of therapeutics and diagnostics.Explore more
AltPep Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AltPep your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AltPep recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AltPep launches new products
Congratulate Masked Content for being promoted to Masked Content at AltPep
Click to see if AltPep had a recent Job posting/layoffs
Funding: Get notified immidiatlly once AltPep has new funding data
Check out if AltPep is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if AltPep has recently received funding, and reach out quickly before it becomes old news!
AltPep, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at AltPep
Find more new buyers
Compare Similar Companies to AltPep
Compare insights from companies similar to AltPep, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AltPep is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AltPep is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AltPep.
AltPep financials insights
Gather financial insights about AltPep, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$23.1M
2022
Other Financing Round
$44.4M
2023
Series B
$52.9M
AltPep Tech Stack
A closer look at the technologies used by AltPep
Most Recent Scoops
Pain Point
Project
, according to a high-level source in financial planning, is planning to remediate challenges related to data storage and management. The organization will focus remediation efforts on improving data security.
Pain Point, Data Center, Storage, Information Security, Database, Infrastructure, Data Management, Financial Planning, Cyber Security, Data Warehousing, Security, Finance, Financial Strategy
Pain Point
, according to a high-level source in financial planning, is experiencing challenges related to board reporting.
Pain Point, Business Intelligence, Financial Planning, Board of Directors, Financial Reporting, Finance, Financial Strategy
Project
, according to a high-level source in financial planning, has completed initiatives related to workforce planning within the last twelve months.
Financial Planning, Employee Relations, Workforce Management, Finance, Financial Strategy, HR Operations
Project
, according to a high-level source in financial planning, has completed initiatives related to board reporting within the last twelve months.
Business Intelligence, Financial Planning, Board of Directors, Financial Reporting, Finance, Financial Strategy
Project
Spending/Investment, Data Management, Data Science, Financial Planning, Compliance, Finance, Financial Strategy
AltPep News & Media
AltPep Corporation Welcomes Denis Sirringhaus as Vice President of Business Development
SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Denis Sirringhaus has joined the company as Vice President of Business Development. “We are thrilled to welcome Denis to our team,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “Denis’ expertise is perfectly aligned to drive the partnerships essential for AltPep to achieve its mission of transAltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease
SEATTLE--(BUSINESS WIRE)--AltPep Corporation (“AltPep” or the “Company”), a privately held biotechnology company dedicated to early disease-modifying treatments and detection tools for amyloid diseases, today announced that the peer-reviewed Nature journal Scientific Reports has published new results from the Company’s evaluation of its novel SOBA-AD blood test, aimed at detecting Alzheimer’s disease (AD). The data, consistent with an earlier study, further support the potential value of the SOAltPep Appoints Soon Hyouk Lee to Newly Created Position of Chief Business Officer
SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep. In this role, Soon will lead AltPep’s corporate and business development. “We are excited about Soon joining our team,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “His experience as both an investor and operator, toAltPep Further Strengthens Advisory Board with Appointment of Steven E. Kahn, M.B., Ch.B.
SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of Steven E. Kahn, M.B., Ch.B. to its Advisory Board. The Advisory Board consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease, other neurodegenerative disorders and now diabetes. “We are thrilled to add Dr. Kahn’s deep clinical and research
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AltPep
Sign Up For FreeTo access detailed company insights
AltPep Corporation is a biotechnology company focused on developing early disease-modifying treatments and detection tools for amyloid diseases, including Alzheimer's and Parkinson's. Their innovative platform utilizes custom-designed synthetic peptides to selectively target and neutralize toxic oligomers associated with these diseases. AltPep aims... Read More
